A large and increasing fraction of orally administered small molecules in pharma company pipelines have poor oral absorption due to low aqueous solubility or dissolution rate. To address this trend, evaluating formulation approaches for increasing oral bioavailability are becoming routine early on in formulation development programs. Amorphous solid dispersions (ASDs) are a prevalent technology for addressing oral bioavailability challenges, given the applicability and scalability of the technology across a diverse compound property space.
Learn more about
- Formulation screening strategies for amorphous solid dispersions
- Details on an integrated approach for developing ASDs including performance, stability and manufacture
- Strategy for incorporating ASDs into dosage forms, including a novel dosage form architecture for ASDs
